

**Research Collaboration between Kyoto University and Shionogi  
at Kyoto University's open innovation laboratory  
– Drug discovery and medical research for the treatment of psychiatric disorders –**

---

**OSAKA, Japan, March 26, 2018** - National University Corporation Kyoto University (Administrative office: Kyoto; President: Juichi Yamagiwa, Ph.D.; hereafter “Kyoto University”) Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that we have entered into a research collaborative agreement, focused on drug discovery and medical research for the treatment of psychiatric disorders.

Under this agreement, Kyoto University and Shionogi will conduct collaborative research activities for a period of five years to gain better understanding and extensive knowledge for the treatment of psychiatric disorders by research on the brain neural networks in different symptoms accompanied with psychiatric disorders, which cause difficulties in patients' lives. Furthermore, through the obtained knowledge, Kyoto University and Shionogi will pursue to identify novel drug targets and to generate innovative new drugs. This SK Project will be carried out at the open innovation laboratory of Kyoto University, the Medical Innovation Center within the Graduate School of Medicine and controlled by a joint research committee established by both entities.

Since April 2013, Kyoto University and Shionogi have been operating the project of “Drug discovery and medical research for the regeneration of synapses and neuronal function” (the SK project) for a period of five years until its completion at the end of this March. In the upcoming project of “Drug discovery and medical research for the treatment of psychiatric disorders”, which is the following phase of the SK project, Kyoto University and Shionogi will dedicate to elucidate the association between psychiatric disorders and brain neural networks and to identify innovative new drugs, by working closely together in both areas of basic and clinical research with activation of researchers interaction and the enhanced intellectual exchange.

Shionogi has its vision, “Grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improving healthcare”, and is striving to contribute to the better health and QOL of people all over the world by promoting open innovation with academia and innovative companies in addition to our own R&D activities.

For further information, contacts:

Corporate Communications, Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Medical Innovation Center, Kyoto University Graduate School of Medicine

Telephone: +81-75-751-0909